Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 Oct;63(10):4191–4194. doi: 10.1128/iai.63.10.4191-4194.1995

Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections.

P L Fidel Jr 1, J L Cutright 1, J D Sobel 1
PMCID: PMC173593  PMID: 7558342

Abstract

Studies to date with CBA/J mice suggest a limited role for systemic cell-mediated immunity (CMI) against vaginal Candida albicans infections. The results of the present study show that preinduced Candida-specific systemic CMI was equally nonprotective against C. albicans vaginal infections in mice with high (BALB/cJ), low (DBA/2), or intermediate (CBA/J) resistance to C. albicans infections. Similarly, the locally acquired partial protection against a second C. albicans vaginal infection was equally observed with BALB/cJ, DBA/2, and CBA/J mice. These results indicate that observations made previously with CBA/J mice were not murine strain specific and provide additional support for the hypothesis that systemic CMI does not represent a dominant host defense mechanism at the vaginal mucosa.

Full Text

The Full Text of this article is available as a PDF (176.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clift R. A. Candidiasis in the transplant patient. Am J Med. 1984 Oct 30;77(4D):34–38. [PubMed] [Google Scholar]
  2. Fidel P. L., Jr, Lynch M. E., Conaway D. H., Tait L., Sobel J. D. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun. 1995 Feb;63(2):547–553. doi: 10.1128/iai.63.2.547-553.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fidel P. L., Jr, Lynch M. E., Redondo-Lopez V., Sobel J. D., Robinson R. Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis. J Infect Dis. 1993 Dec;168(6):1458–1465. doi: 10.1093/infdis/168.6.1458. [DOI] [PubMed] [Google Scholar]
  4. Fidel P. L., Jr, Lynch M. E., Sobel J. D. Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect Immun. 1993 Oct;61(10):4202–4207. doi: 10.1128/iai.61.10.4202-4207.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fidel P. L., Jr, Lynch M. E., Sobel J. D. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect Immun. 1993 May;61(5):1990–1995. doi: 10.1128/iai.61.5.1990-1995.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fidel P. L., Jr, Lynch M. E., Sobel J. D. Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis. Infect Immun. 1995 Jul;63(7):2403–2408. doi: 10.1128/iai.63.7.2403-2408.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fidel P. L., Jr, Lynch M. E., Sobel J. D. Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect Immun. 1994 Mar;62(3):1032–1038. doi: 10.1128/iai.62.3.1032-1038.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fong I. W., McCleary P., Read S. Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis. Am J Obstet Gynecol. 1992 Mar;166(3):887–890. doi: 10.1016/0002-9378(92)91356-f. [DOI] [PubMed] [Google Scholar]
  9. Hector R. F., Domer J. E., Carrow E. W. Immune responses to Candida albicans in genetically distinct mice. Infect Immun. 1982 Dec;38(3):1020–1028. doi: 10.1128/iai.38.3.1020-1028.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hobbs J. R., Brigden D., Davidson F., Kahan M., Oates J. K. Immunological aspects of candidal vaginitis. Proc R Soc Med. 1977;70 (Suppl 4):11–14. [PMC free article] [PubMed] [Google Scholar]
  11. Klein R. S., Harris C. A., Small C. B., Moll B., Lesser M., Friedland G. H. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984 Aug 9;311(6):354–358. doi: 10.1056/NEJM198408093110602. [DOI] [PubMed] [Google Scholar]
  12. Knight L., Fletcher J. Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteroids, and diabetes mellitus. J Infect Dis. 1971 Apr;123(4):371–377. doi: 10.1093/infdis/123.4.371. [DOI] [PubMed] [Google Scholar]
  13. Macher A. M. The pathology of AIDS. Public Health Rep. 1988 May-Jun;103(3):246–254. [PMC free article] [PubMed] [Google Scholar]
  14. Sobel J. D. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann N Y Acad Sci. 1988;544:547–557. doi: 10.1111/j.1749-6632.1988.tb40450.x. [DOI] [PubMed] [Google Scholar]
  15. Syverson R. E., Buckley H., Gibian J., Ryan G. M., Jr Cellular and humoral immune status in women with chronic Candida vaginitis. Am J Obstet Gynecol. 1979 Jul 15;134(6):624–627. doi: 10.1016/0002-9378(79)90641-0. [DOI] [PubMed] [Google Scholar]
  16. Witkin S. S., Hirsch J., Ledger W. J. A macrophage defect in women with recurrent Candida vaginitis and its reversal in vitro by prostaglandin inhibitors. Am J Obstet Gynecol. 1986 Oct;155(4):790–795. doi: 10.1016/s0002-9378(86)80022-9. [DOI] [PubMed] [Google Scholar]
  17. Witkin S. S., Yu I. R., Ledger W. J. Inhibition of Candida albicans--induced lymphocyte proliferation by lymphocytes and sera from women with recurrent vaginitis. Am J Obstet Gynecol. 1983 Dec 1;147(7):809–811. doi: 10.1016/0002-9378(83)90044-3. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES